Kajian Literatur: Perbandingan Efektivitas Antiplatelet Kombinasi Aspirin-Clopidogrel dan Aspirin pada Stroke Iskemik

Literature Review: Comparison of the Antiplatelet Effectiveness of the Aspirin-Clopidogrel Combination and Aspirin in Ischemic Stroke

Authors

  • Salwa Octariani Laboratorium Penelitian dan Pengembangan Kefarmasian “Farmaka Tropis”, Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia
  • Dewi Mayasari Laboratorium Penelitian dan Pengembangan Kefarmasian “Farmaka Tropis”, Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia
  • Adam M. Ramadhan Laboratorium Penelitian dan Pengembangan Kefarmasian “Farmaka Tropis”, Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia

DOI:

https://doi.org/10.25026/mpc.v14i1.597

Keywords:

Aspirin, Aspirin and Clopidogrel, Ischemic Stroke

Abstract

Ischemic stroke is a condition resulting from a lack of blood flow to the brain. One of the therapies used for ischemic stroke is antiplatelet. Single antiplatelet therapy is generally preferred over combination antiplatelet therapy, because combination therapy results in increased bleeding, which outweighs any benefits. Various studies on the effectiveness of antiplatelet between the combination of aspirin and clopidogrel with aspirin in ischemic stroke patients have been carried out. However, until now there is no consensus that the outcome is better between single aspirin therapy with the aspirin-clopidogrel combination. The aim of this study was to compare the effectiveness of the combination aspirin-clopidogrel and aspirin in ischemic stroke. The method used in this study is a literature review using Google Scholar, PubMed, and Science Direct databases. From the 5 literature that has been reviewed, it shows that in patients with minor ischemic stroke the combination of aspirin-clopidogrel is more effective than single aspirin which is seen from several parameters including Modified Rankin Scale (mRS), European Quality of Life – 5 Dimension (EQ-5D), National Institute of Health Stroke Scale (NIHSS), Activated Partial Thromboplastin Time (aPTT), leukocyte platelet aggregation and leukocyte-platelet aggregate.

References

Parmar, P. 2011. Stroke Classification and Diagnosis. Royal Pharmaceutical Society, Volume XI: 45-67.

Albay, Christessa Emille Que, Frederick Gavril D. Leyson, and Federick C. Cheng. 2020. Dual Versus Mono Antiplatelet Therapy for Acute Non-Cardio Embolic Ischemic Stroke or Transient Ischemic Attack, an Efficacy and Safety Analysis-Updated Meta-Analysis. BMC Neurology 20 (1): 1-11

Bain, Amie. 2018. Antiplatelet Use in Practice. British Journal of Cardiac Nursing 13 (6): 272-278

Degrauwe, S., Pilgrim, T., Aminian, A., Noble, S., Meier, P., & Iglesias, J. F. 2017. Dual Antiplatelet Therapy for Secondary Prevention of Coronary Artery Disease: Open heart, 4(2).

Simamora, Roymond H. 2008. Buku Ajar Pendidikan Dalam Keperawatan.Jakarta: Buku Kedokteran EGC

Diener, H. C., et al. 2004. Aspirin and Clopidogrel Compared with Clopidogrel Alone After Recent Ischaemic Stroke or Transient Ischaemic Attack in High-Risk Patients (MATCH): Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 364(9431), 331-337.

Wang, Yongjun, et al. 2013. Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack. N Engl J Med, 369, 11-19.

Powers, W. J., et al. 2018. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke, 49(3), e46-e99

Johnson, Walter, Oyere Onuma, Mayowa Owolabi, dan Sonal Sach. 2016 "Stroke: a Global Response is Needed. Bulletin of the World Health Organization 94(9): 634.

Wang, Xianwei, et al. 2015. Effect Of Clopidogrel With Aspirin on Functional Outcome in TIA Or Minor Stroke: CHANCE Substudy. Neurology 85 (7): 573-579.

Cucchiara, Brett, et al. 2020. Disability After Minor Stroke and Transient Ischemic Attack in The POINT Trial. Stroke 51(3): 792-799.

Yi, Xingyang, et al. 2014. A Comparative Study of Dual Versus Monoantiplatelet Therapy in Patients With Acute Large-Artery Atherosclerosis Stroke. Journal of Stroke and Cerebrovascular Diseases 23 (7): 1975-1981.

He, Fan, et al. 2015. Clopidogrel Plus Aspirin Versus Aspirin Alone for Preventing Early Neurological Deterioration in Patients With Acute Ischemic Stroke. Journal of Clinical Neuroscience (22) 1: 83-86.

Xie, X., et al. 2019. Effect of Dual Versus Mono Antiplatelet Therapy on Recurrent Stroke Modulated by Activated Partial Thromboplastin Time. European Journal of Neurology 26 (9): 1168-e78.

Ibrahim, E. A. A., and M. A. M. Ahmed. 2019. The Outcome of Acute Ischemic Stroke in Sudanese Patients on Dual Anti-platelet Therapy Clopidogrel and Aspirin vs. Aspirin Using Modified Ranking Scale at the National Centre for Neurological Science. J Neurol Neurosurg Psychiatry Res 1 (105)

Wilson JL, Hareendran A, Grant M, et al. 2002. Improving the Assessment of Outcomes in Stroke: Use of a Structured Interview to Assign Grades on the Modified Rankin Scale. Stroke. 33 (9): 2243–2246.

Mendelow, A. David. 2015. Stroke: Pathophysiology, Diagnosis,aAnd Management. Elsevier Health Sciences,

Gusi, N., Olivares, P. R., Rajendram, R., Preedy, V. R., dan Watson, R. R. 2010. Handbook of Disease Burdens and Quality of Life Measures. New York, NY: Springer New York, 87-99.

Lu, Wen-Shian, et al. 2016. Convergent Validity And Responsiveness Of The EQ-5D Utility Weights For Stroke Survivors. Journal Of Rehabilitation Medicine 48(4): 346-351.

Marsh, Elisabeth B., et al. 2016. The NIH Stroke Scale Has Limited Utility in Accurate Daily Monitoring of Neurologic Status. The Neurohospitalist 6(3): 97-101.

Sucharew, Heidi, et al. 2013. Profiles of The National Institutes of Health Stroke Scale Items as a Predictor Of Patient Outcome. Stroke 44(8): 2182-2187.

Elsaid Reham AbdElhamed AbdElmawla dan Amina Mohamed AbdElfatah Sliman. 2020. Physiological Parameters Deterioration in Acute Stage After Stroke: Rehabilitation Versus Conventional Care. Journal of Nursing Education and Practice 10 (3)

Fateh-Moghadam, Suzanne, et al. 2007. Hyperresponsiveness of Platelets in Ischemic Stroke. Thrombosis And Haemostasis 97(06): 974-978.

Sabra, Ahmed, et al. 2016. Assessment of Platelet Function in Patients with Stroke Using Multiple Electrode Platelet Aggregometry: A Prospective Observational Study. BMC Neurology 16(1): 1-8.

Stegner, David, Vanessa Klaus, dan Bernhard Nieswandt. 2019. Platelets as Modulators of Cerebral Ischemia/Reperfusion Injury. Frontiers in Immunology 10: 2505.

Maclouf, Jacques, et al. 1984. Arachidonic Acid-Induced Human Platelet Aggregation Independent Of Cyclooxygenase And Lipoxygenase. Prostaglandins 28(3): 383-398.

Levy, Jerrold H., et al. 2014. Clinical Use of The Activated Partial Thromboplastin Time And Prothrombin Time for Screening: A Review of The Literature and Current Guidelines for Testing. Clinics in Laboratory Medicine 34(3): 453-477.

Lin, H. C., Kuo, W. Y., dan Kuo, Y. C. 2015. Shortened Activated Partial Thromboplastin Time Is Associated With Acute Ischemic Stroke, Stroke Severity, and Neurological Worsening. Journal of Stroke and Cerebrovascular Disease 24(10): 2270 – 2276.

Levy, Jerrold H. dan Andrew McKee. 2007. Bleeding, Hemostasis, and Transfusion Medicine. Cardiothoracic Critical Care: 437.

Lin, Yu-Chuan, et al. 2019. Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog. Arteriosclerosis, Thrombosis, And Vascular Biology, 39.4: 694-703

Rudinga, G. Rwibasira, Khan, G. J., dan Kong, Y. 2018. Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy. International journal of molecular sciences, 19(2), 573.

Downloads

Published

2021-12-31

How to Cite

Octariani, S., Mayasari, D., & Ramadhan, A. M. (2021). Kajian Literatur: Perbandingan Efektivitas Antiplatelet Kombinasi Aspirin-Clopidogrel dan Aspirin pada Stroke Iskemik: Literature Review: Comparison of the Antiplatelet Effectiveness of the Aspirin-Clopidogrel Combination and Aspirin in Ischemic Stroke. Proceeding of Mulawarman Pharmaceuticals Conferences, 14(1), 405–412. https://doi.org/10.25026/mpc.v14i1.597

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>